Five-year survival data: Brentuximab vedotin may be curative in some with Hodgkin lymphoma

(American Society of Hematology) This multinational Phase II study examines brentuximab vedotin (BV) in patients with Hodgkin lymphoma who relapsed after stem cell transplant. The study reports that 13 of 34 (38 percent) patients who achieved complete remission have remained disease-free for over five years and may be cured. Of those patients, nine received only single-agent BV. These data were published in Blood, the journal of the American Society of Hematology (ASH).
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news